On December 11, the 6th Fudan Zhongshan Patent Salon & the 1st Medical Science Innovation and Translation Training Course, themed "Integrating Medicine, Research, and Industry, Empowering New Development," was grandly held at Zhongshan Hospital Affiliated to Fudan University (hereinafter referred to as "Zhongshan Hospital"). The event attracted over 500 industry elites from medical institutions, enterprises, and research units nationwide. Attendees included Hou Yan, Chairman of the China Association of Medical Equipment; Wu Jinglei, President of the Shanghai Medical Association; Fan Jia, Academician of the Chinese Academy of Sciences and Honorary President of Zhongshan Hospital; Zhou Jian, Academician of the Chinese Academy of Sciences and President of Zhongshan Hospital; along with representatives from approximately thirty enterprises and platforms, as well as scientific innovation management personnel from numerous domestic hospitals.

During the conference, Academician Zhou Jian, President of Zhongshan Hospital and a member of the Chinese Academy of Sciences, signed the 2025 Key Scientific and Technological Achievement Transformation Agreement on behalf of the hospital with enterprise representatives. Junshi Biotechnology, a wholly-owned subsidiary of Dunwill Medical, entered into an in-depth collaboration with the Endoscopy Center team led by Professor Zhong Yunshi at Zhongshan Hospital. This partnership aims to jointly promote the clinical translation and application of a technology that utilizes molecular characteristics of microRNA from endoscopic biopsy samples for predicting precise diagnosis and treatment of colorectal cancer. Ms. Wen Dong, CEO of Dunwill Medical, participated in the signing ceremony as an enterprise representative.

In the subsequent session, Song Zhenju, Vice President of Zhongshan Hospital, systematically presented the hospital's phased progress in scientific innovation and translation, fully demonstrating the effectiveness of the scientific and technological ecosystem constructed by the hospital. President Song specifically highlighted in his report that the "7 MicroRNA Test Kit" (miRNA7), jointly developed by Zhongshan Hospital and Dunwill Medical and successfully launched, is a significant representative achievement of collaborative innovation integrating medicine, research, and industry. The sensitivity of this kit for diagnosing very early-stage liver cancer is approximately 30% higher than that of traditional markers, providing an efficient and precise detection tool for the early screening and auxiliary diagnosis of hepatocellular carcinoma. As the first Class III liver cancer molecular diagnostic product approved by the National Medical Products Administration (NMPA) in China, miRNA7 possesses completely independent intellectual property rights. It has obtained invention patents in Hong Kong, South Korea, and Japan, as well as an international PCT patent. It has been honored with significant awards including the Second Prize of the National Science and Technology Progress Award and the First Prize of the Shanghai Science and Technology Progress Award. Currently, this product is being clinically applied in over 200 top-tier hospitals across more than 20 provinces in China, fully validating the successful pathway from top-tier clinical scientific discovery to mature in vitro diagnostic (IVD) products.

As a comprehensive National Medical Center construction unit, Zhongshan Hospital has been deeply engaged in the field of innovation translation for many years with remarkable results. Since 2022, the hospital has filed over 3,200 patent applications, obtained more than 1,700 patents granted, and successfully translated over 400 patents, leading the industry in both translation efficiency and quality. In 2025, the hospital was rated as a "National Leading Hospital in Medical Innovation Translation," setting a practical benchmark for scientific innovation in public hospitals.

In recent years, Dunwill Medical and Zhongshan Hospital have continuously deepened their strategic cooperation. Through this powerful alliance and complementary advantages, they have successfully translated multiple original, clinically-grade IVD products with independent intellectual property rights. This latest collaboration focusing on a deep infiltration prediction model for colorectal cancer represents a continuation and deepening of their joint efforts in the field of cutting-edge molecular diagnostics. Dunwill Medical will fully leverage its extensive experience in IVD reagent research and development, translational lean production, and regulatory registration to transform the top-tier clinical research expertise of Zhongshan Hospital into reliable, clinically relevant diagnostic products, once again bridging the path "from the laboratory to the bedside."

In the future, Dunwill Medical will continue to collaborate with clinical experts, further deepen cooperation, promote the acceleration of more "from 0 to 1" medical breakthroughs towards "from 1 to N" widespread application, ensure that high-quality innovative achievements benefit a broad patient population, and solidify the foundation of innovation for the Healthy China initiative.